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Abstract.  Candida  infections  are  the  most  frequent  infections  in  neutropenic  patients. 
Hepatosplenic  candidiasis  (HSC)  is  a  part  of  disseminated  Candida  infection  that  occurs  most 
commonly  in  patients  with  hematologic  malignancies  treated  with  chemotherapy  and  requires 
protracted  antifungal  therapy.  During  invasive  mycosis  with  rapid  resolution  of 
immunosuppression,  immune  reconstitution  inflammatory  syndrome  (IRIS)  which  mimics 
treatment  failure,  drug  toxicity  or  breakthrough  infections  may  occur.  Manifestation  period, 
histopathologic findings and favorable effect of steroids to its inflammatory symptoms strongly 
suggest that HSC belongs to the invasive fungal infection induced IRIS. 
We present a child with B cell-acute lymphoblastic leukemia who developed HSC and addition of 
corticosteroid therapy to antifungal treatment achieved rapid resolution of the clinical symptoms 
and laboratory findings. 
 
Introduction.  Hepatosplenic  candidiasis,  also  called 
“chronic disseminated candidiasis” is a part of severe 
invasive  Candida  infection  with  prominent 
involvement of the liver, spleen and occasionally the 
kidneys and other organs.
1,2 During rapid resolution of 
immunosuppressive conditions,  immune reconstitution 
inflammatory  syndrome  (IRIS),  an  exaggerated 
inflammatory  response  to  some  opportunistic 
microorganisms  such  as  Mycobacterium tuberculosis, 
Histoplasma  capsulatum,  Cryptococcus  neoformans, 
Aspergillus  species  may  occur.
3-5  Hepatosplenic 
candidiasis  share  several  features  with  IRIS  related 
with  invasive  fungal  infections  such  as  occurrence 
during  neutrophil  recovery,  histopathologic  findings 
and the beneficial effect of steroids to its inflammatory 
symptoms.  These features strongly suggest that HSC 
belongs to the invasive fungal infection induced IRIS.
6 
Here,  we  report  a  case  of  HSC  developing  an 
exaggerated inflammatory  response during neutrophil 
recovery after leukemia induction therapy. Addition of 
corticosteroid  therapy  to  antifungal  therapy  has 
achieved  a  rapid  and  complete  resolution  of  clinical 
and laboratory findings.  
 
Case  Report:  16-month  old  boy  diagnosed  with 
standard-risk  precursor  B  cell-acute  lymphoblastic 
leukemia was initiated induction therapy of ALL BFM 
95  treatment  protocol  which  consisted  of  prednisone 
(60 mg/m²/day for day 1-28, and tapering for day 29-
37), daunorubicin (30 mg/m²/day for day 8 and 15), L-Mediterr J Hematol Infect Dis 2012; 4: Open Journal System   
 
asparaginase (5,000 U/m²/day for day 12, 15, 18, 21, 
24, 27, 30 and 33), vincristine (1,5 mg/m²/day for day 
8, 15, 22 and 29) and intratechal methotrexate (at age-
adjusted dose for day 1, 12 and 33).
6 On day 15, bone 
marrow  aspiration  revealed  <5%  blast,  slightly 
decreased  cellularity  with  lymphocyte  predominance. 
On  the  17
th  day  of  therapy,  he  developed  febrile 
neutropenia  and  imipenem/cilastatin  (60  mg/kg/day) 
and vancomycin (40 mg/kg/day) was commenced. On 
day  20,  fluconazole  (loading  dose  12  mg/kg/day  iv, 
followed  by  6  mg/kg/day  q  24  hr  iv)  was  added  to 
therapy  because  of  persistent  fever  and  mild  oral 
moniliasis.  On  day  22,  he  developed  tachypnea;  at 
physical  examination rales were present.     Despite  a 
presumptive  diagnosis  of  pneumonia,  computed 
tomography  (CT)  of  thorax  and  abdominal 
ultrasonography were unremarkable. Blood and urine 
cultures and galactomannan antigen were all negative. 
Although  oral  moniliasis  resolved,  fever  and  rales 
persisted and repeated thorax CT demonstrated several 
ground  grass  areas  and  a  5mm  nodular  lesion 
surrounded by ground-glass opacity.  For a  possible 
Aspergillus infection, fluconazole therapy was shifted 
to voriconazole (loading dose 6 mg/kg/dose 2 doses, 
maintenance dose 4 mg/kg/dose iv 2 doses) on day 25.  
His condition improved shortly thereafter.  Induction 
chemotherapy was completed along with antibiotic and 
antifungal treatment despite persistence of fever. In the 
interim,  his  leukocyte  count,  serum  alkaline 
phosphatase  (ALP),  serum  γ-glutamyl  transferase 
(GGT)  and  serum  C-reactive  protein  (CRP)  levels 
began to rise, and reached their top values including 
leukocyte  count  of  36.1x10
9/L,  ALP  of  1096  U/L 
(normal  range,  145-420  U/L),  GGT  of  674  U/L 
(normal  range,  5-32  U/L)  and  CRP  of  23  mg/dl 
(normal  range,  0.08-1.12  mg/dl).  Peripheral  blood 
smear  revealed  neutrophilia  without  any  blast.    At 
abdominal  ultrasonography  multiple  hypoechoic 
millimetric  hepatic  nodules  were  noted  (Figure  1).  
Despite  his  good  clinical  condition,  persistence  of 
fever, elevated ALP and  CRP levels  and hypoechoic 
ultrasonographic  images  in  the  liver,  led  us  to  the 
diagnosis  of  possible  HSC.
7  Although  the  use  of 
antibacterial,  antifungal  drugs  and  chemotherapeutics 
in  our  patient  might  have  caused  hepatotoxicity  and 
therefore  mimic  laboratory  findings  of  HSC, 
combination  of  clinical,  laboratory  and  radiological 
findings  following  neutrophil  recovery  led  us  to  the 
diagnosis  of  HSC.  Dexamethasone  (0,5  mg/kg)  was 
added  to  voriconazole  therapy.  Fever  disappeared  in 
three  days  period  and  leukocyte  count,  serum  ALP, 
GGT and CRP levels were normalized within 7 days. 
Corticosteroid therapy was, thereafter, tapered in a 7 
days  period  and  stopped.  Hypoechoic  ultrasound 
images in the liver disappeared 30 days after initiation  
 
Figure  1.  The  sonographic  appearance  of  multiple  hypoechoic 
millimetric hepatic nodules. 
 
Figure  2.  Hepatic  ultrasound  image  30  days  after  initiation  of 
corticosteroid therapy. 
of  corticosteroid  therapy  (Figure  2).  Antifungal 
therapy  in  combination  with  chemotherapy  was 
continued  for  three  months.  He  is  currently  in 
remission and receiving maintenance therapy of BFM. 
 
Discussion:  Hepatosplenic  candidiasis  has  been 
reported  in  cancer  patients  particularly  with  acute 
leukemia  during  neutropenia.
8-10  It  is  often  clinically 
apparent during neutrophil recovery.
9 The frequency of 
HSC has been reported between 3-29% depending on 
the  diagnostic  criteria.
10  Although  not  specific  for 
HSC,  young  age,  neutropenia  (absolute  neutrophil 
count <500 µL) lasting more than 15 days, and the use 
of  prophylactic  quinolones  have  been  reported  to  be 
independent  risk  factors  for  both  acute  and  chronic 
invasive  candidiasis.
10  It  has  been  hypothesized  that 
HSC develops as a result of prolonged neutropenia and 
gastrointestinal  mucosal  damage  in  the  context  of 
immune dysregulation due to defective coordination of 
Th1/Th2 response  in conjunction  with other  immune Mediterr J Hematol Infect Dis 2012; 4: Open Journal System   
 
imbalance.
3,10  Recently  Th1/Th17  pathway  has  been 
implicated  in  the  pathogenesis  of  fungal  infection 
related IRIS.
11 There has been increased recognition of 
the role of endogenous levels of certain cytokines such 
as IL-10, IL-17, IL-23 and some immunomodulators as 
likely  contributing  factors  in  the  pathogenesis  of 
systemic candidal infection.
6,10,11 
A diagnosis of HSC should be suspected with fever 
unresponsive  to  broad-spectrum  antibiotics  during 
neutropenic stage and following its recovery, and the 
presence of symptoms and physical findings including 
upper  abdominal  pain,  tenderness,  jaundice,  and 
hepatosplenomegaly.    Increased  serum  liver  function 
tests,  abnormal  hepato-splenic  imaging  at  CT  or 
ultrasonography  and  histopathologic  evidence  of 
Candida  spp.  in  the  biopsy  specimens  make  the 
diagnosis  of  HSC.
10  Furthermore,  clinical/laboratory 
evidence of other infections and/or clinical conditions 
such  as  progressive  infection,  drug  toxicity  or 
breakthrough infections should be excluded.  
Amphotericine B is accepted as the initial agent of 
choice for HSC. Alternative options include the use of 
azoles  particularly  fluconazole,  voriconazole  and 
echinocandins.
12,13 Therapy should be continued until 
calcification  or  resolution  of  lesions,  particularly  in 
patients    receiving  continued  chemotherapy  or 
immunosuppression.
12  Hepatosplenic  candidiasis 
requires  several  months  of  antifungal  therapy,  thus 
interrupt the treatment of underlying leukemia. Delay 
in the treatment of leukemia may affect the course and 
survival  of  these  patients.  As  recently  reported, 
addition of corticosteroid therapy to antifungal therapy 
in  patients  with  HSC  related  IRIS  has  found  to  be 
associated  with  disappearance  of  clinical  symptoms, 
radiologic abnormalities and inflammatory markers.
6,14 
It was  supposed that corticosteroids might adjust the 
paradoxical  immune  response  by  modulating  both 
mononuclear phagocyte function and T-cell activation.
6 
In our case, we observed that adjuvant corticosteroid 
therapy, in addition to antifungal treatment, provided a 
rapid and complete resolution of clinical and laboratory 
and subsequently radiological findings. 
In  conclusion,  HSC-related  IRIS  should  be 
suspected  in  febrile  immune  compromised  patients 
especially during neutrophil recovery with exaggerated 
inflammatory  response  and  persistent  symptoms 
despite receiving antifungal therapy. It should be kept 
in  mind  that,  addition  corticosteroid  therapy  to 
appropriate antifungal treatment may result in prompt 
resolution of clinical and laboratory findings. 
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